Human IgG Lambda MAb kit
Human IgG Lambda quantification for bioprocess applications
The CD16a (FcgRIIIa, V158) cellular binding assay is a simple and robust test to monitor binding of the IgG Fc region to the human CD16a receptor in live cells and to select the most potent antibody for use in Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). The assay can also be used to assess the degree of antibody afucosylation. Two separate CD16a assays are available to specifically target the V158 or F158 variants. These assays, based on our innovative Tag-lite technology, can easily be automated to create a high-throughput solution for predicting ADCC.
The CD16a receptor cellular binding assays (FcgIIIa V158 or F158) present only 1 incubation step after reagents distribution. Lumi4-terbium Cryptate pre-labelled cells are dispensed, followed by the addition of IgG1 labelled with d2 and the sample. After 2h incubation at RT, the signal can be read.
Increasing concentrations of unlabeled IgGs were incubated in presence of a constant concentration of d2-labeled IgG1. The plate was then read on a PHERAstar microplate reader (BMG Labtech). As previously described, we confirm that the affinity of IgG1 for CD16a is better than that of IgG3 and considerably higher than IgG2 and IgG4 (Bruhns et al., Blood 2009).
In collaboration with Vivalis - Scientific Presentations
In collaboration with Roche - Scientific Presentations
profile and study your Fcg receptor - Flyers
In collaboration with BioTek - Posters
In collaboration with Roche Glycart - Posters
Characterizing therapeutic antibodies - Posters
Tag-lite® CD16a cellular binding assays - Flyers
Get the brochure about technology comparison. - Brochures